🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thank you to PMAC and the incredible mentors I have there including Massimo Cristofanilli, MD, FACP Aditya Bardia, MD Arielle Medford, MD Lorenzo Gerratana Carolina Reduzzi and many others, as well as Guardant Health for their support of this research. Find our rapid oral abstract here: meetings.asco.org/abstracts-pres…

.ESMO - Eur. Oncology recommendations for the use of NGS is published in Annals of Oncology . >200 references ! Breast cancer is one of the new indications. A special mention is done for tumor-agnostic indications. A big work from @fermosele and the precision medicine group of ESMO

Antibody Drug Conjugate, SG, enables sequential TOP1/PARP inhibitor strategy & highlights need to revisit previously abandoned combos with chemotherapy. Translational team collaboration Mass General Cancer Center Dana-Farber’s Breast Oncology Center #bcsm Full text ⁦Clinical Cancer Research⁩ aacrjournals.org/clincancerres/…

The new antibody drug conjugate Dato-DXd was found to improve outcomes in metastatic ER+ #breastcancer. New data from TROPION-Breast01 trial at #ASCO24 show Dato-DXd led to fewer side effects compared to chemotherapy alone

The ASCO #ASCO_LDP reception last night was 🔥! Thank you ASCO for investing in LDP- a completely transformative experience!

Javier Cortes MD PhD conclusions in EBC: 🤔 Carbo clearly needed in high risk TNBC, maybe we should try omitting anthracyclines now that we have immuno here. 👏 ISPY design of selecting size of therapy based on tumors response is a great way to personalize treatment #ASCO24 #bcsm

ISPY2.2 Dato-DXd + durvalumab beautifully presented by Rebecca Shatsky, MD. After 4 cycles neoadj Dato/durva, 4/42 pts w/ HR+ and 21/64 pts w/ HR- stage II/III EBC achieved pCR. 43% pCR in immune+ subtype, meeting graduation threshold. Grateful to participate in this innovate trial & to

Honored to participate in an ASCO OncLive.com Peer Direct panel on Advances in HR+ HER2- mBC with my esteemed colleagues Drs Hurvitz, Pegram and VIRGINIA KAKLAMANI. Go to OncLive.com to see our finished production. Thank you to organizers for the opportunity!

Thank you for the invitation MOASC Enjoyed the conversation Ashkan Sumanta K. Pal, MD, FASCO

Congratulations Rachel Occhiogrosso Abelman, MD on the YIA and support from Conquer Cancer, the ASCO Foundation to continue the important work on ADC sequencing in MBC. #RisingStar

My old friend Aditya Bardia, MD and new friend Dr. Melissa Davis talking about breast cancer disparities at the Mass General Cancer Center 3rd Annual Cancer Equity Colloquium, running through tomorrow. Much work to do together.

Excited to see the upcoming early-phase ADC data at #ESMO24. Only 8 weeks away!! (Abstracts will be published on Monday, 9 September)

Kick off of the 2024 #DAVAbreast davaonc.com/davabreast2024 with Hawaiian oli blessing. 175 talks on novel therapeutics in #breastcancer

Dava meeting available online now. Live discussions by many luminaries about existing and future work in breast cancer. Goes through Saturday morning. ⁦OncoAlert⁩ #Davabreast

Great work at Siteman Cancer Center and Fred & Pamela Buffett Cancer Center presented by Jairam Krishnamurthy and Dr. Nusayba Bagegni demonstrating that incomplete TKa suppression at C1D15 may identify pts with CDK 4/6i resistant tumors Two trials with DiviTum ongoing: clinicaltrials.gov/study/NCT04968… clinicaltrials.gov/study/NCT05977…

The 2024 Kona Breast Cancer Summit started yesterday. I must say this is the best networking event, a place to seek new ideas and establish collaboration for breast cancer oncologists and researchers in the USA. #davabreast

The DAVA Oncology 2024 #breastcancer Summit in beautiful 🏝️ #Kona, #Hawaii, was truly exceptional! 🌺 IMO, it was the most special #breastcancer meeting, where junior faculty had the unique opportunity to meet, network, and collaborate with the giants of breast oncology. Huge applause

My Top 10 Breast Cancer Abstracts list at #ESMO24 👇

What's the new ADC data coming up from ESMO 24 ? Puxitatug samrotecan ( anti -B7-H4 ADC ) probably looks most promising . Rinatabart Sesutecan already has FDA fast track Designation ( FR-alpha ADC ) New Cludin6 and Claudin 18.2 ADC, Anti Her2 ADC and Trop 2 ADC data needs to

Two weeks to #ESMO24. Multiple important breast onc trials readouts across disease subtypes, including OS from KN522, DB12, 4y of NATALEE, CAPItello290, phase 1 studies of novel ADCs, IO, targeted drugs, and so much more. The countdown is on. See you soon in Barcelona! 🇪🇸 #bcsm